Authors


Isabella Ciccone, MPH

Latest:

What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.


James M. Crosby, DO

Latest:

Exploring the Recently Approved and Upcoming Clostridioides difficile Therapeutics

This market has seen a flurry of activity, as shown by a review of the latest agents.


Shmuel Shoham, MD

Latest:

COVID-19 Convalescent Plasma: What Is Its Role in Therapy?

The key is using the right dose on the right patient at the right time.


Jianxiang Xia, MD

Latest:

INSTIs and Cardiovascular Outcomes: More Complexity

The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.


Aleena Issac, PharmD

Latest:

Treating Persistent Methicillin-susceptible Staphylococcus aureus (MSSA) Bacteremia

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).


Torey Roesch, MD

Latest:

A Review of the Currently Available Monoclonal Antibodies for COVID-19

Outside of vaccines, these underutilized therapies are the best defense against severe disease.


Heather Platt, MD

Latest:

European Commission Approves Merck's Capvaxive for Adult Pneumococcal Disease Prevention

New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.


Eric Gregory, PharmD, BCIDP

Latest:

Vancomycin AUC Implementation in Resource-Limited Settings and its Associated Difficulties

The latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.


Moupali Das, MD, MPH

Latest:

Gilead's Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study

New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention


Julia Donahue, PharmD

Latest:

Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission

Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.



Gavin H. Harris, MD

Latest:

Now is Not the Time for Funding Pauses, Cutting Ties With Health Organizations

Biocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.


Caitlin Hart, PharmD

Latest:

When Should We De-Escalate Empiric Antimicrobials?

De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.


Alice Gallo De Moraes, MD

Latest:

Opposing Forces During COVID-19: Perspective From the ICU

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.


Daniel Escobar, MD

Latest:

Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to Miss

Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.


Carter Keller

Latest:

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.


Donald Alcendor, PhD

Latest:

COVID-19 Booster Shots and the Future

Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.


Katelyn Kennedy, PharmD

Latest:

Oral Carbapenems: Promise, Peril, and Pushbacks

Here is a review of the literature for this class of antibiotics.


Albert Bach, PharmD

Latest:

What’s New With Non–COVID-19 Vaccines

Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.


Jina Saltzman, PA-C

Latest:

Lessons in Resilience: What HIV Teaches Us About COVID-19

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.


Jonathan Alicea

Latest:

Still Learning: Optimizing the Diagnosis and Screening of Respiratory Viruses

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.


Lauren R. Biehle, PharmD, BCPS, BCIDP

Latest:

When Should We De-Escalate Empiric Antimicrobials?

De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.


Bradley Langford, PharmD, BCIDP

Latest:

SHARE the Responsibility of Antibiotic Stewardship With Our Patients

How pharmacists can use shared decision-making to improve antibiotic use.


Erin Torrance, PharmD candidate

Latest:

Respiratory Syncytial Viral Infection: Treatment With Ziresovir in Infants

Findings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.


Natalie Tucker, PharmD, BCIDP

Latest:

A Day Late and a Dollar Short: Managing Antimicrobial Drug Shortages

With antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.


Priya Nori, MD

Latest:

Practice Pearls for Treatment of Respiratory Infections

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.


John Koethe, MD

Latest:

Multidisciplinary Perspectives on HIV Treatment

A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.


Crystal K. Hodge, PharmD, BCIDP

Latest:

The Pendulum of Progress: Soft Skills in Whole Person Clinical Training

These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.



Takako S. Schaninger, MD

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.

© 2025 MJH Life Sciences

All rights reserved.